Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.

Treating to a target of clinical remission or low disease activity is an important principle for managing rheumatoid arthritis (RA). Despite the availability of biologic disease-modifying antirheumatic drugs (bDMARDs), a substantial proportion of patients with RA do not achieve these treatment targe... View More